Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?

Expert Rev Clin Pharmacol. 2021 Oct;14(10):1189-1192. doi: 10.1080/17512433.2021.1942843. Epub 2021 Jun 19.

Authors

Theocharis Koufakis¹, Nikolaos Papanas², Pantelis Zebekakis¹, Kalliopi Kotsa¹

Affiliations

¹ Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece.
² Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

PMID: 34120551
DOI: 10.1080/17512433.2021.1942843

No abstract available

Publication types

Editorial

MeSH terms

Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Humans
Hypoglycemic Agents / administration & dosage*
Metformin / administration & dosage*
Primary Prevention / methods

Substances

Hypoglycemic Agents
Metformin